Taylor SJ - Search Results

1

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.

Taylor SJ, Thien CB, Dagger SA, Duyvestyn JM, Grove CS, Lee BH, Gilliland DG, Langdon WY. Taylor SJ, et al. Exp Hematol. 2015 Mar;43(3):191-206.e1. doi: 10.1016/j.exphem.2014.11.009. Epub 2014 Dec 19. Exp Hematol. 2015. PMID: 25534201 Free article.

2

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.

Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY. Taylor SJ, et al. Blood. 2012 Nov 8;120(19):4049-57. doi: 10.1182/blood-2012-06-436675. Epub 2012 Sep 18. Blood. 2012. PMID: 22990016 Free article.

3

Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.

Duyvestyn JM, Taylor SJ, Dagger SA, Orandle M, Morse HC 3rd, Thien CB, Langdon WY. Duyvestyn JM, et al. Among authors: taylor sj. PLoS One. 2014 Apr 9;9(4):e94717. doi: 10.1371/journal.pone.0094717. eCollection 2014. PLoS One. 2014. PMID: 24718698 Free PMC article.

4

Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.

Duyvestyn JM, Taylor SJ, Dagger SA, Langdon WY. Duyvestyn JM, et al. Among authors: taylor sj. Exp Hematol. 2016 May;44(5):410-421.e5. doi: 10.1016/j.exphem.2016.02.008. Epub 2016 Feb 26. Exp Hematol. 2016. PMID: 26921649 Free article.

5

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

Taylor SJ, Duyvestyn JM, Dagger SA, Dishington EJ, Rinaldi CA, Dovey OM, Vassiliou GS, Grove CS, Langdon WY. Taylor SJ, et al. Sci Transl Med. 2017 Aug 9;9(402):eaam8060. doi: 10.1126/scitranslmed.aam8060. Sci Transl Med. 2017. PMID: 28794285

6

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY. Oksvold MP, et al. Among authors: taylor sj. Exp Hematol. 2015 May;43(5):352-363.e4. doi: 10.1016/j.exphem.2015.01.008. Epub 2015 Jan 29. Exp Hematol. 2015. PMID: 25641047 Free article.

7

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.

Taylor SJ, Langdon WY. Taylor SJ, et al. Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017. Mol Cell Oncol. 2017. PMID: 29209657 Free PMC article.

8

Sleeping through the storm: Preventing myelosuppression with quizartinib.

Taylor SJ, Langdon WY. Taylor SJ, et al. Oncotarget. 2017 Sep 30;8(51):88255-88256. doi: 10.18632/oncotarget.21395. eCollection 2017 Oct 24. Oncotarget. 2017. PMID: 29179431 Free PMC article. No abstract available.

9

IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. Mitchell K, et al. Among authors: taylor sj. J Exp Med. 2018 Jun 4;215(6):1709-1727. doi: 10.1084/jem.20180147. Epub 2018 May 17. J Exp Med. 2018. PMID: 29773641 Free PMC article.

10

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism.

Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. Ueda K, et al. Among authors: taylor sj. Cancer Cell. 2021 Apr 12;39(4):529-547.e7. doi: 10.1016/j.ccell.2021.02.006. Epub 2021 Mar 4. Cancer Cell. 2021. PMID: 33667384 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

456 results

Search Page